By admin 
Means, who served as a high-level advisor within the White House and across federal health agencies until his abrupt resignation last month, painted a bleak picture of a reform agenda derailed by a "violent" pushback from industrial giants. His testimony serves as a post-mortem of sorts for a policy initiative that promised to dismantle the "chronic disease industrial complex" but found itself ensnared in the same web of lobbying and political expediency it sought to untangle. According to Means, the American public is being "duped and gaslighted and lied to" by a symbiotic relationship between Big Food, Big Pharma, and the federal bureaucracy.
The centerpiece of Means’ critique focused on the administration’s handling of glyphosate, the world’s most widely used herbicide and the primary ingredient in Roundup. For the MAHA movement, glyphosate represents more than just a chemical; it is a symbol of the systemic poisoning of the American food supply. Proponents of the movement point to a growing body of international research suggesting links between glyphosate exposure and various cancers, gut microbiome disruption, and endocrine issues. However, when Means attempted to initiate high-level reviews of the substance or suggest restrictions on its use, he encountered what he described as an "almost violent reaction" from industry groups and their allies within the administration.
The conflict reached a breaking point when a senior White House official reportedly presented Means with a policy directive aimed not at restricting glyphosate, but at aggressively boosting its production and export. When Means questioned the move, citing its direct contradiction to the MAHA platform’s goals of reducing toxic exposure, he was told the policy was "not up for discussion." This moment, Means suggests, was the realization that the administration’s economic and trade priorities, heavily influenced by the multi-billion-dollar agricultural lobby, would always take precedence over public health concerns.
To understand the weight of these allegations, one must look at the data surrounding corporate influence in Washington. According to OpenSecrets, the pharmaceutical and health products industry spent over $380 million on lobbying in 2023 alone, while the agribusiness sector contributed another $170 million. These sectors do not merely lobby for favorable legislation; they fund the very scientific research that federal agencies like the FDA and USDA use to determine safety standards. This "funding effect" often leads to regulatory outcomes that favor industry profitability over consumer safety. In the case of glyphosate, Bayer (which acquired Monsanto in 2018) has spent billions of dollars in legal settlements and lobbying efforts to maintain the chemical’s market dominance, despite the World Health Organization’s International Agency for Research on Cancer (IARC) classifying it as "probably carcinogenic to humans" in 2015.
Means’ resignation highlights the inherent tension within the Trump administration’s broader "MAGA" coalition. On one side are the traditionalists who prioritize deregulation, industrial expansion, and the protection of American exports. On the other are the MAHA reformers, led by Kennedy and Means, who argue that the economic cost of the chronic disease epidemic—estimated at $4.5 trillion annually in the United States—far outweighs the profits of the food and chemical industries. They argue that the U.S. is facing an existential crisis: 74% of adults are overweight or obese, 1 in 2 adults has pre-diabetes or Type 2 diabetes, and rates of autoimmune diseases and neurodevelopmental disorders are skyrocketing.
During the Rogan interview, Means argued that the federal government is incentivized to maintain the status quo. He pointed to the "revolving door" between regulatory agencies and the private sector, where officials move from high-ranking government posts to lucrative roles in the industries they once regulated. This creates a culture of compliance where regulators are hesitant to challenge the status quo for fear of jeopardizing their future career prospects. Means specifically criticized the USDA’s "Checkoff Programs," which use government authority to collect fees from farmers to fund marketing campaigns for commodities like beef, pork, and dairy—effectively turning the government into a marketing arm for Big Ag.
The MAHA agenda sought to reform these structures by decoupling industry funding from regulatory science, banning the use of certain chemicals already prohibited in Europe, and restructuring the Farm Bill to subsidize organic and regenerative farming rather than the monocrops of corn and soy that fuel the ultra-processed food industry. However, Means suggests that these proposals were met with a wall of resistance from the "permanent state" of lobbyists and career bureaucrats who view any disruption to the industrial food system as a threat to national economic stability.
Expert perspectives on Means’ departure vary, but many health advocates see it as a significant blow to the movement’s credibility. "Calley Means was the intellectual engine behind the MAHA policy framework," said one former public health official who spoke on the condition of anonymity. "His resignation suggests that the movement’s ideas were fundamentally incompatible with the administration’s broader economic alliances. You cannot claim to want to ‘Make America Healthy Again’ while simultaneously protecting the companies that are making America sick."
The political fallout of this rift is yet to be fully realized. Robert F. Kennedy Jr., who remains a prominent figure in the administration’s orbit, now faces the difficult task of maintaining the MAHA momentum without his key strategist. For Kennedy’s base—a diverse coalition of health-conscious voters, environmentalists, and anti-establishment skeptics—Means’ resignation is a confirmation of their worst fears: that the "swamp" is too deep to be drained, even by those who promised to do so.
In the final segments of the podcast, Means issued a call to action for the American public, urging them to look past partisan politics and recognize the shared threat of the chronic disease epidemic. He argued that the current healthcare system is not a "health" system at all, but a "sickness" system that profits from the management of chronic conditions rather than their prevention or cure. He cited the fact that the U.S. spends more on healthcare than any other nation, yet ranks near the bottom of developed countries in life expectancy and maternal mortality.
The "glyphosate directive" mentioned by Means serves as a microcosm of the larger struggle. It illustrates how specific policy decisions are often made in silos, where economic advisors prioritize trade balances and commodity prices without consulting health experts about the long-term medical costs of those decisions. If the U.S. continues to subsidize the production of toxic chemicals and ultra-processed ingredients, the MAHA movement argues, the nation will eventually be bankrupted by its own medical bills.
As the administration moves forward, the question remains whether any of the MAHA goals can be salvaged. Some insiders suggest that Kennedy may still be able to influence policy through executive orders or by placing allies in mid-level agency positions. However, without a cohesive strategy and the support of the White House’s senior economic team, these efforts may be relegated to the margins.
Means’ departure and subsequent public testimony mark a turning point in the conversation about American health. By exposing the internal mechanics of how industry influence thwarts reform, he has provided a roadmap for future advocates who seek to challenge the status quo. Whether the MAHA movement can survive this internal fracture or if it will be remembered as a brief, failed experiment in populist health reform remains to be seen. For now, the "violent" reaction of the industry, as described by Means, stands as a testament to the power of the corporate interests that continue to shape the health and future of the American people.
